Assessing the Therapeutic Outcomes and Safety Profile of Topical Steroids in Pediatric Atopic Dermatitis: A Cohort Study

Authors

  • Hira Zahid
  • Zaeem Nazar
  • Asma Hussain
  • Asma Bano
  • Zahida Perveen
  • Asjid Jabbar

Keywords:

N\A

Abstract

Objective: To evaluate the efficacy and safety of topical corticosteroids in treating pediatric patients with atopic dermatitis (AD) in Pakistan, and to determine the optimal treatment regimen based on patient response.

Methods: This prospective cohort study was conducted at Jinnah Hospital, a tertiary care hospital in Lahore, Pakistan, over a period of 12 months. A total of 150 pediatric patients, aged 1–12 years, diagnosed with moderate-to-severe atopic dermatitis were enrolled. Participants were treated with different strengths of topical corticosteroids (mild, moderate, and potent) based on the severity of their condition. Treatment efficacy was assessed by the reduction in the Eczema Area and Severity Index (EASI) score and clinical improvement, while safety was monitored through the occurrence of side effects, such as skin thinning, striae, and delayed wound healing. Follow-up visits were scheduled at 2, 4, and 8 weeks, with data collection at each visit.

Results:Of the 150 enrolled patients, 140 completed the study. The mean age of participants was 6.2 ± 3.1 years, with 60% being male. After 8 weeks of treatment, 85% of patients showed significant improvement in their EASI scores, with a 70% reduction in overall severity. In the group using mild corticosteroids, 75% of patients showed improvement, whereas 90% of patients using moderate to potent corticosteroids experienced better outcomes. However, 15% of patients using moderate to potent corticosteroids developed mild side effects such as skin thinning and delayed wound healing, which resolved upon discontinuation of therapy. No severe side effects, including adrenal suppression or growth retardation, were observed.

Conclusion:Topical corticosteroids are an effective treatment for pediatric atopic dermatitis in Pakistan, with moderate to potent steroids showing the best clinical outcomes. However, close monitoring for side effects is essential, particularly in patients requiring higher-potency steroids. Further studies with a larger sample size and long-term follow-up are recommended to confirm these findings and determine the long-term safety of corticosteroid use in children..

Downloads

Download data is not yet available.

References

1. Williams HC, Stang PE, Bowen L, et al. Atopic dermatitis and the influence of the skin microbiome. J Invest Dermatol. 2017;137(4):769-775.

2. Irfan M, Sulaiman K, Ahsan S, et al. Prevalence of atopic dermatitis in children: A hospital-based study in Pakistan. J Pakistan Assoc Dermatol. 2018;28(2):108-113.

3. Graft DF, Wong KA, David M, et al. Topical corticosteroids in pediatric atopic dermatitis: A review of clinical use and safety. Dermatology. 2020;236(6):478-485.

4. Haeberle C, Papadopulos E, Sauter B, et al. Corticosteroid use in pediatric patients with atopic dermatitis: Efficacy and safety. Pediatr Dermatol. 2019;36(4):482-489.

5. Charman CR, Vickery C, Clark CJ, et al. The role of topical steroids in the treatment of pediatric atopic dermatitis. Clin Exp Dermatol. 2019;44(5):583-589.

6. Eichenfield LF, Tom WL, Chamlin SL, et al. Atopic dermatitis: Pathogenesis and treatment. J Am Acad Dermatol. 2014;70(2):338-348.

7. Fitzpatrick T, Polderman A, Brons S, et al. Side effects of topical corticosteroids in children: A review of 40 years of data. Pediatr Dermatol. 2018;35(6):658-666.

8. Charman CR, Vickery C, Clark CJ, et al. The role of topical corticosteroids in pediatric atopic dermatitis. J Dermatol Treat. 2020;31(5):530-537.

9. Roth J, Vollhardt H, Enzmann H, et al. Systemic side effects of topical corticosteroids in pediatric dermatology. Pediatrics. 2017;140(3):e20171718.

10. Squires RH, et al. Safety and efficacy of corticosteroid therapy in children with atopic dermatitis. Pediatr Dermatol. 2017;34(5):485-491.

11. Beattie PE, Lewis-Jones MS, Haq Z, et al. The role of emollients in the management of pediatric atopic dermatitis. Clin Dermatol. 2020;38(1):72-79.

12. Brunner PM, Finkelstein Y, Guttman-Yassky E, Maher H, Singh R, Verma S, et al. Topical calcineurin inhibitors in the treatment of atopic dermatitis. Dermatology. 2020;236(5):477-486.

13. Ghosh S, Arora R, Kaur H, Sharma S, Singh A, Bhatt A, et al. Safety and efficacy of topical corticosteroids in children: A 5-year follow-up study. Pediatr Dermatol. 2018;35(3):270-275.

14. Cho S, Lee J, Park J, Kwon J, Lee J, Hong H, et al. Systemic absorption of topical corticosteroids in pediatric patients: A pharmacokinetic review. Dermatol Ther. 2020;33(2):e13487.

15. Choi H, Kim H, Lee Y, Park Y, Jang K, Lee M, et al. The role of topical immunomodulators in pediatric atopic dermatitis: A systematic review. Pediatr Dermatol. 2021;38(2):299-308.

16. Liu J, Wang Y, Xu X, Zhang Q, Li S, Yang L, et al. Novel treatments for pediatric atopic dermatitis: The role of topical immunosuppressive agents. J Dermatol Treat. 2021;32(6):715-722.

Downloads

Published

2025-12-30

How to Cite

1.
Zahid H, Nazar Z, Hussain A, Bano A, Perveen Z, Jabbar A. Assessing the Therapeutic Outcomes and Safety Profile of Topical Steroids in Pediatric Atopic Dermatitis: A Cohort Study. J Neonatal Surg [Internet]. 2025 Dec. 30 [cited 2026 Jan. 20];14(33S):257-61. Available from: https://jneonatalsurg.com/index.php/jns/article/view/9796

Issue

Vol. 14 No. 33S (2025): Journal of Neonatal Surgery

Section

Original Article

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

You are free to:

  • Adapt — remix, transform, and build upon the material for any purpose, even commercially.

Terms:

  • Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  • No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.